Tyrosine Protein Kinase JAK1 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Immunology, Dermatology, and Gastrointestinal which include the indications Rheumatoid Arthritis, Psoriasis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, and Ulcerative Colitis, Inflammatory Bowel Disease. It also reviews key players involved in Tyrosine Protein Kinase JAK1 targeted therapeutics development with respective active and dormant or discontinued products.

The Tyrosine Protein Kinase JAK1 pipeline targets constitutes close to 60 molecules. Out of which, approximately 59 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, Preclinical, Discovery, and Unknown stages are 9, 3, 16, 25, 31, 2, 8, 24, 5, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Tyrosine Protein Kinase JAK1 overview

JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

For a complete picture of Tyrosine Protein Kinase JAK1’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.